On Wednesday 17 September, the European Commission announced that it had granted EU market authorisation for zuranolone, a medicine designed to treat post-partum depression (PPD).
This mental health condition can affect women following childbirth and is marked by persistent sadness, anxiety and fatigue. It can be severe and long-lasting, with negative consequences for both mother and child.
To date, no specific treatment has been approved for PPD, and standard antidepressants often do not...